PMID- 35397088
OWN - NLM
STAT- MEDLINE
DCOM- 20220506
LR  - 20220515
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 76
IP  - 2
DP  - 2022 May
TI  - Changes of Th17 cells, regulatory T cells, Treg/Th17, IL-17 and IL-10 in patients 
      with type 2 diabetes mellitus: a systematic review and meta-analysis.
PG  - 263-272
LID - 10.1007/s12020-022-03043-6 [doi]
AB  - PURPOSE: The aim of this study was to investigate the changes of Helper T cells 
      17 (Th17 cells), Regulatory T cells (Treg cells), Treg/Th17, Interleukin-17 
      (IL-17) and Interleukin-10 (IL-10) in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: Four electronic resource databases were searched from their 
      inception to 1 August 2021. Case-control studies about changes of Th17 cells, 
      Treg cells, Treg/Th17, IL-17 and IL-10 in patients with T2DM were retrieved. We 
      performed this meta-analysis via RevMan V.5.3 and Stata14. RESULTS: 20 studies 
      with 1242 individuals were included in the meta-analysis. Compared with the 
      controls, the patients with T2DM had significantly increased levels of percentage 
      of Th17 cells (SMD, 1.74; 95% CI, 0.47-3.01; p < 0.001), IL-17 (SMD, 2.17; 95% 
      CI, 0.06-4.28; p < 0.001), IL-10 (SMD, 1.20; 95% CI, 0.81-1.59; p = 0.003), but 
      decreased levels of percentage of Treg cells (SMD, -1.17; 95% CI, -2.22 to -0.13; 
      p < 0.001) and Treg/Th17 ratio (SMD, -4.43; 95% CI, -7.07 to -1.78; p < 0.001). 
      Subgroup analysis showed that percentage of CD4(+)CD25(+)FOXP3(+) Tregs (SMD, 
      -2.36; 95% CI, -3.19 to -1.52; p = 0.003) in patients was notably lower than 
      controls. While not significant changes were found in the percentage of 
      CD4(+)CD25(+)Tregs (SMD, 0.03; 95% CI, -0.34-0.40; p = 0.63) between patients and 
      controls. For plasma or serum IL-10, a higher plasma IL-10 level (SMD,1.37; 95% 
      CI, 0.92-1.82; p = 0.01) was observed in T2DM. While serum IL-10 (SMD, 0.73; 95% 
      CI, 0.35-1.12; p = 0.79) had no obvious difference between patients and controls. 
      For ELISA or flow cytometry, IL-10 (SMD, 1.2; 95% CI, 0.71-1.70; p = 0.001) was 
      higher in T2DM patients by using detection method of ELISA. Yet IL-10 using flow 
      cytometry and subgroup analysis of IL-17 had no significant differences. 
      CONCLUSIONS: Adaptive immune system indeed plays an essential role in the process 
      of T2DM. Imbalance between Th17 and Treg triggers pro-inflammatory environment in 
      patients with T2DM.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Zi, Changyan
AU  - Zi C
AUID- ORCID: 0000-0001-5369-6812
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      611137, Chengdu, PR China. zichangyan@stu.cdutcm.edu.cn.
FAU - He, Lisha
AU  - He L
AD  - School of Basic Medical Sciences, Chengdu University of Traditional Chinese 
      Medicine, 611137, Chengdu, PR China. jqhelisha@163.com.
FAU - Yao, Huan
AU  - Yao H
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      611137, Chengdu, PR China.
FAU - Ren, Yuan
AU  - Ren Y
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      611137, Chengdu, PR China.
FAU - He, Tingting
AU  - He T
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      611137, Chengdu, PR China.
FAU - Gao, Yongxiang
AU  - Gao Y
AD  - School of International Education, Chengdu University of Traditional Chinese 
      Medicine, 610075, Chengdu, PR China. drgaoyx@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220409
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Interleukin-17)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Interleukin-10
MH  - Interleukin-17
MH  - *T-Lymphocytes, Regulatory
MH  - Th17 Cells
OTO - NOTNLM
OT  - IL-10
OT  - IL-17
OT  - Meta-analysis
OT  - Regulatory T cells
OT  - T2DM
OT  - Th17 cells
EDAT- 2022/04/10 06:00
MHDA- 2022/05/07 06:00
CRDT- 2022/04/09 12:03
PHST- 2022/01/13 00:00 [received]
PHST- 2022/03/19 00:00 [accepted]
PHST- 2022/04/10 06:00 [pubmed]
PHST- 2022/05/07 06:00 [medline]
PHST- 2022/04/09 12:03 [entrez]
AID - 10.1007/s12020-022-03043-6 [pii]
AID - 10.1007/s12020-022-03043-6 [doi]
PST - ppublish
SO  - Endocrine. 2022 May;76(2):263-272. doi: 10.1007/s12020-022-03043-6. Epub 2022 Apr 
      9.